Comparison Study in the Treatment of Uterine Fibroids Uterine Fibroid Embolization Using BeadBlock™ Embolic Agent

Overview

A double arm (non-inferiority) 44 patient study to assess the performance of BeadBlock™ in the treatment of uterine fibroids by embolization with respect to clinical & imaging outcome with comparison of primary safety endpoints to Embosphere.

Full Title of Study: “Feasibility Evaluation of the Embolic Agent BeadBlock™ in the Treatment of Uterine Fibroids With Uterine Artery Embolization With Comparison of Study Endpoints to Embosphere®”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Triple (Participant, Care Provider, Investigator)
  • Study Primary Completion Date: March 2010

Detailed Description

The purpose of the study is to conduct a comparison between BeadBlock™ and Embosphere in uterine fibroid embolization. Baseline and follow-up MR Imaging data will be made with respect to changes in fibroid and uterus perfusion and fibroid and uterine volume. This is a 12 months study (12 month follow up for all enrollees). The primary end-point will be the degree of fibroid devascularization as seen at contrast-enhanced MRI performed 3 months (+/- 15 days) after UAE procedure. In addition we will assess symptom reduction in patients that have undergone uterine fibroid embolization with Bead Block™ and Embosphere®. Primary Objective 1. To assess the change in fibroid devascularization as seen at contrast-enhanced MRI performed after UAE and at three (3) months (+/- 15 days) following the UAE, and compare the changes between BeadBlock™ and Embosphere. Secondary Objective 1. To assess the change in fibroid devascularization as seen at contrast-enhanced MRI performed several days after UAE and 6 months (+/- 15 days) following the UAE, and compare the changes between BeadBlock™ and Embosphere. Tertiary Objective 1. To assess the change in uterine volume as seen at contrast-enhanced MRI performed several days after UAE, 3 months (+/- 15 days) and 6 months (+/- 15 days) following the UAE, and compare the changes between BeadBlock™ and Embosphere. 2. To assess the change from baseline in symptom severity (UFS-QOL)at 3, 6 and 12 months (+/- 15 days) follow-up, as measured by the subscale of the UFS questionnaire, and compare the changes between BeadBlock™ and Embosphere.

Interventions

  • Device: Uterine fibroid embolization BeadBlock™
    • Intervention with BeadBlock Microspehere
  • Device: Uterine fibroid embolization Embosphere®
    • Embosphere – control arm

Arms, Groups and Cohorts

  • Experimental: 1
    • BeadBlock treatment arm
  • Active Comparator: 2
    • Embospheres control arm

Clinical Trial Outcome Measures

Primary Measures

  • Change in fibroid devascularization as seen at contrast enhanced MRI performed several days after UAE and 3 months following the UAE between BeadBlock™ and Embosphere
    • Time Frame: 12 months

Secondary Measures

  • Mean difference of change in fibroid devascularization CEMRI performed several days after UAE and 6 months following the UAE between BeadBlock™ and Embosphere.
    • Time Frame: 12 months
  • assess the change from baseline in symptom severity (UFS-QOL)at 3, 6 and 12 months (+/- 15 days) follow-up
    • Time Frame: 12 months

Participating in This Clinical Trial

Inclusion Criteria

1. Patient chooses to participate and has signed informed consent 2. Age between 30 and 50 years old 3. Symptoms caused by uterine fibroids, such as heavy bleeding (menorrhagia) and/or bulk-related complaints such as urinary frequency, constipation or pelvic pain. 4. Patient has fibroids confirmed by MRI 5. Patient has normal kidney function. 6. Patient is willing and able to undergo follow-up imaging at 3 and 6 months post UFE. Exclusion Criteria:

1. Patients who are pregnant or plan to become pregnant within the study period, or desire future fertility. 2. Patients with a history of gynecologic malignancy 3. Patients with known endometrial hyperplasia 4. Patients with adenomyosis 5. Patients with pelvic inflammatory disease 6. Patients with Uteri < 250 ml (cm) calculated volume or > 24 weeks 7. Patients with pedunculated subserosal fibroids with a narrow attachment (<50% diameter of the fibroid) to the uterus. 8. Patients with pelvic pain as dominant syndrome 9. Known allergy to contrast media that cannot be adequately pre-medicated. 10. Patients not suitable for arterial access. 11. Previous uterine artery embolization attempts. 12. History of pelvic irradiation. 13. Patients on GnRH Therapy within 3-6 months prior to the study enrollment.

Gender Eligibility: Female

Minimum Age: 30 Years

Maximum Age: 50 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Worthington-Kirsch, Robert L., M.D.
  • Collaborator
    • Terumo Medical Corporation
  • Provider of Information About this Clinical Study
    • Robert Worthington-Kirsch MD, Image Guided Surgery associates
  • Overall Official(s)
    • Robert Worthington-Kirsch, MD, Principal Investigator, Image Guided Surgery Associates

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.